ArQule Inc. (ARQL)

7.77
0.20 2.51
NASDAQ : Health Technology
Prev Close 7.97
Open 8.10
Day Low/High 7.74 / 8.14
52 Wk Low/High 2.23 / 12.22
Volume 1.97M
Avg Volume 3.18M
Exchange NASDAQ
Shares Outstanding 120.26M
Market Cap 950.05M
EPS -0.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of ARQL April 2020 Options Trading

First Week Of ARQL April 2020 Options Trading

Investors in ArQule Inc. saw new options become available this week, for the April 2020 expiration.

ArQule Reports Second Quarter 2019 Financial Results

ArQule Reports Second Quarter 2019 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2019.

ArQule To Participate In The BTIG Biotechnology Conference On Monday, August 12, 2019

ArQule To Participate In The BTIG Biotechnology Conference On Monday, August 12, 2019

ArQule, Inc. (Nasdaq:ARQL) today announced that Dr.

ArQule To Present At The SVB Leerink Spotlight Series: Rare & Genetic Diseases On August 8, 2019

ArQule To Present At The SVB Leerink Spotlight Series: Rare & Genetic Diseases On August 8, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr.

ArQule To Report Second Quarter 2019 Financial Results On August 7, 2019

ArQule To Report Second Quarter 2019 Financial Results On August 7, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter of 2019 before the market opens on Wednesday, August 7, 2019.

ArQule Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

ArQule Announces Closing Of Public Offering And Full Exercise Of Option To Purchase Additional Shares

ArQule, Inc. (Nasdaq: ARQL) today announced the closing of its previously announced underwritten public offering of common stock, including the exercise in full by the underwriters of their option to purchase an additional 1,387,500 shares at the public...

ArQule Announces Pricing Of $90 Million Public Offering Of Common Stock

ArQule Announces Pricing Of $90 Million Public Offering Of Common Stock

ArQule, Inc. (Nasdaq:ARQL) today announced the pricing of an underwritten public offering of 9,250,000 shares of its common stock at a price to the public of $9.

ArQule Announces Commencement Of Proposed Public Offering Of Common Stock

ArQule Announces Commencement Of Proposed Public Offering Of Common Stock

ArQule, Inc. (Nasdaq: ARQL) today announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

ArQule To Present At The BMO Prescriptions For Success Healthcare Conference On June 25, 2019

ArQule To Present At The BMO Prescriptions For Success Healthcare Conference On June 25, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 at 8:00 a.

ArQule Announces Preliminary Results From Its Phase 1/2 Study Of Miransertib (ARQ 092), In Patients With PIK3CA-related Overgrowth Spectrum (PROS) And Proteus Syndrome (PS) In An Oral Presentation At The European Society Of Human Genetics Conference

ArQule Announces Preliminary Results From Its Phase 1/2 Study Of Miransertib (ARQ 092), In Patients With PIK3CA-related Overgrowth Spectrum (PROS) And Proteus Syndrome (PS) In An Oral Presentation At The European Society Of Human Genetics Conference

ArQule, Inc. (Nasdaq:ARQL) today announced preliminary results from the company's phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an oral presentation...

ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results

ArQule Jumps on Positive Phase 1 Blood Cancer Trial Results

The company is testing its hematologic malignancies treatment.

ArQule Announces Clinical Proof-of-Concept Data From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies At The 2019 EHA Annual Meeting

ArQule Announces Clinical Proof-of-Concept Data From Ongoing Phase 1 Study Of Reversible BTK Inhibitor, ARQ 531, In Patients With Relapsed/Refractory Hematologic Malignancies At The 2019 EHA Annual Meeting

ArQule, Inc. (Nasdaq: ARQL) today announced preliminary results from the Company's phase 1 dose escalation study for ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton's tyrosine kinase (BTK) in...

ArQule Announces Oral Presentation For Its Pan-AKT Inhibitor, Miransertib, At The 2019 European Society Of Human Genetics (ESHG) Conference

ArQule Announces Oral Presentation For Its Pan-AKT Inhibitor, Miransertib, At The 2019 European Society Of Human Genetics (ESHG) Conference

ArQule, Inc. (Nasdaq:ARQL), today announced it will present preliminary results from the company's phase 1/2 study of its pan-AKT inhibitor, miransertib (ARQ 092), in patients with PIK3CA-related Overgrowth Spectrum (PROS) and Proteus syndrome (PS) in an...

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 24th Congress Of The European Hematology Association (EHA)

ArQule To Present Clinical Data For Its BTK Inhibitor, ARQ 531, At The 24th Congress Of The European Hematology Association (EHA)

ArQule, Inc. (Nasdaq: ARQL), today announced that it will present clinical data from the company-sponsored phase 1 dose escalation study on its BTK inhibitor, ARQ 531, for the treatment of relapsed or refractory B-cell lymphoid malignancies in a poster...

ArQule To Present At The Jefferies 2019 Healthcare Conference On June 6, 2019

ArQule To Present At The Jefferies 2019 Healthcare Conference On June 6, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, Peter Lawrence, President and Chief Operating Officer, and Marc Schegerin, Chief Financial Officer and Head of Strategy, will present at the Jefferies 2019 Healthcare...

First Week Of ARQL January 2020 Options Trading

First Week Of ARQL January 2020 Options Trading

Investors in ArQule Inc. saw new options become available this week, for the January 2020 expiration.

ArQule To Present At The 20th Annual B. Riley FBR Institutional Investor Conference On May 22, 2019

ArQule To Present At The 20th Annual B. Riley FBR Institutional Investor Conference On May 22, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Dr.

ArQule To Present At The 2019 RBC Capital Markets Global Healthcare Conference On May 21, 2019

ArQule To Present At The 2019 RBC Capital Markets Global Healthcare Conference On May 21, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr.

ArQule To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On May 15, 2019

ArQule To Present At The Bank Of America Merrill Lynch 2019 Health Care Conference On May 15, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr.

ArQule Reports First Quarter 2019 Financial Results

ArQule Reports First Quarter 2019 Financial Results

ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the first quarter, 2019.

Sinovant Sciences Announces Approval Of Derazantinib's Clinical Trial Application By The China National Medical Products Administration

Sinovant Sciences Announces Approval Of Derazantinib's Clinical Trial Application By The China National Medical Products Administration

ArQule, Inc.'s (Nasdaq: ARQL) partner, Sinovant Sciences, announced that its Clinical Trial Application (CTA) for derazantinib has been accepted by the Center for Drug Evaluation at the China National Medical Products Administration (NMPA), enabling the...

ArQule To Report First Quarter 2019 Financial Results On May 1, 2019

ArQule To Report First Quarter 2019 Financial Results On May 1, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the first quarter of 2019 before the market opens on Wednesday, May 1, 2019.

Notable Monday Option Activity: ARQL, ASMB, ZAYO

Notable Monday Option Activity: ARQL, ASMB, ZAYO

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in ArQule Inc. , where a total of 12,652 contracts have traded so far, representing approximately 1.3 million underlying shares.

ArQule To Present At 18th Annual Needham Healthcare Conference On April 9, 2019

ArQule To Present At 18th Annual Needham Healthcare Conference On April 9, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Dr.

June 21st Options Now Available For ArQule (ARQL)

June 21st Options Now Available For ArQule (ARQL)

Investors in ArQule Inc. saw new options begin trading today, for the June 21st expiration.

ArQule Announces Management Team Changes

ArQule Announces Management Team Changes

ArQule, Inc. (Nasdaq: ARQL) today announced that Robert Weiskopf, Senior Vice President, Chief Financial Officer and Treasurer, has decided to retire effective March 29 of this year.

ArQule To Present At Oppenheimer's 29th Annual Healthcare Conference On March 20, 2019

ArQule To Present At Oppenheimer's 29th Annual Healthcare Conference On March 20, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Peter Lawrence, President and Chief Operating Officer, and Brian Schwartz, MD, Chief Medical Officer and Head of Research and Development, of ArQule will present at Oppenheimer's 29th Annual Healthcare...

ArQule To Participate In The 31st Annual ROTH Conference On March 17-19, 2019

ArQule To Participate In The 31st Annual ROTH Conference On March 17-19, 2019

ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Marc Schegerin, Senior Vice President and Head of Strategy, Finance and Communication, will participate in the 31st Annual ROTH Conference on March 17-19, 2019 in...

TheStreet Quant Rating: D (Sell)